Novartis AG (NVS)

NVS on New York Consolidated

90.15USD
24 Oct 2014
Price Change (% chg)

$0.91 (+1.02%)
Prev Close
$89.24
Open
$89.81
Day's High
$90.27
Day's Low
$89.69
Volume
616,865
Avg. Vol
1,362,599
52-wk High
$95.50
52-wk Low
$76.36

NVS

Chart for NVS

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.53
Market Cap (Mil.): $242,328.70
Shares Outstanding (Mil.): 2,706.19
Dividend: 2.76
Yield (%): 3.09

Financials

  NVS Industry Sector
P/E (TTM): 23.54 33.08 33.86
EPS (TTM): 3.79 -- --
ROI: 9.76 18.26 17.53
ROE: 13.41 18.93 18.34
Search Stocks

Novartis reports positive results in spinal inflammation condition

ZURICH - Swiss drugmaker Novartis said on Thursday two late-stage trials showed its drug secukinumab improved symptoms of ankylosing spondylitis, a debilitating joint condition of the spine.

23 Oct 2014

Novartis reports positive results in spinal inflammation condition

ZURICH, Oct 23 - Swiss drugmaker Novartis said on Thursday two late-stage trials showed its drug secukinumab improved symptoms of ankylosing spondylitis, a debilitating joint condition of the spine.

23 Oct 2014

UPDATE 2-Roche to spend $3.2 billion on towering Basel base

* To build new R&D centre, office tower, renovate buildings

22 Oct 2014

FDA panel unanimously backs Novartis' psoriasis drug

- An advisory panel to the U.S. Food and Drug Administration unanimously recommended the use of Novartis AG's anti-inflammation drug in patients with a type of psoriasis, paving the way for its approval.

20 Oct 2014

FDA panel unanimously backs Novartis' psoriasis drug

Oct 20 - An advisory panel to the U.S. Food and Drug Administration unanimously recommended the use of Novartis AG's anti-inflammation drug in patients with a type of psoriasis, paving the way for its approval.

20 Oct 2014

Novartis psoriasis drug benefits outweighs risk-FDA staff

- The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

UPDATE 1-Novartis psoriasis drug benefits outweighs risk-FDA staff

Oct 16 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

Benefits of Novartis psoriasis drug outweighs risk: FDA staff

Oct 16 - The benefits of Novartis AG's anti-inflammation drug outweighed the risks in using it to treat a type of psoriasis, staff reviewers at the U.S. Food and Drug Administration said.

16 Oct 2014

BUZZ-Oxford Biomedica: Signs 3-year deal with Novartis

** Oxford Biomedica's shares rise more than 20 pct after the gene-and-cell-based therapeutics maker says it has signed a three-year contract with Novartis AG that could bring in up to $90 million for the British company.

10 Oct 2014

BRIEF-Oxford Biomedica signs further contract with Novartis for LentiVector

* Oxford Biomedica announces new process development and manufacturing collaboration which includes lentivector  licence agreement

10 Oct 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.13 +0.50
Pfizer Inc. (PFE.N) $29.11 +0.51
Merck & Co., Inc. (MRK.N) $57.61 +0.98
Roche Holding Ltd. (ROG.VX) CHF278.00 -1.40
Abbott Laboratories (ABT.N) $42.46 +0.03
Sanofi SA (SASY.PA) €84.60 -0.30
AstraZeneca plc (AZN.L) 4,327.50p -7.00
GlaxoSmithKline plc (GSK.L) 1,415.50p +3.50
Eli Lilly and Co (LLY.N) $66.05 +1.70
Bristol-Myers Squibb Co (BMY.N) $53.63 +1.13

Earnings vs. Estimates

Search Stocks